Immunosuppressive regimens for lung transplantation frequently fail to prevent rejection and are toxic. Alemtuzumab was used as induction to investigate whether oral immunosuppression could be reduced. From November 2006 to March 2008, 20 consecutive lung transplant patients received alemtuzumab induction, with reduced maintenance immunosuppression; tacrolimus (target level 10 ngyml), mycophenolate mofetil (MMF) 250 mg bid and prednisone 7.5 mg. Twenty control cases transplanted before 2006 were treated with standard immunosuppression; tacrolimus (target level 10 ngyml), MMF 750 mg bid and prednisone 15 mg qd. End-points included patient and graft survival, acute rejection (AR) and infection rate. There were no significant differences in six-month and 12-month survival (alemtuzumab 90% vs. controls 95%, Ps0.52 and 76% vs. 95%, respectively, Ps0.19). AR events were similar (alemtuzumab 2y16 vs. controls 5y20, Ps0.43) -as were -bacteria positive bronchoalveolar lavage (BAL) cultures (alemtuzumab 4.9"7.3 per patient per year vs. controls 2.7"3.3, Ps0.26) and viral or fungal infections (alemtuzumab 0.4"1.4 per patient per year vs. controls 0.1"0.3, Ps0.87; alemtuzumab 3.9"6.6 vs. controls 2.3"1.9, Ps0.57, respectively). Alemtuzumab induction and reduced immunosuppression appears to offer comparable early survival, rejection and infection rates to high-dose standard immunosuppression.
Introduction
Although lung transplantation has been a therapeutic option for severe lung disease, outcomes are poor w1x. Significant limitations include rejection and immunosuppressive drug toxicities including nephrotoxicity and opportunistic infections w2x.
Alemtuzumab (Campath-1H; Genzyme, Cambridge, MA, USA) is a humanized anti-CD52 lymphocytic monoclonal antibody. The CD52 antigen is found on lymphocytes, monocytes, macrophages and eosinophils. One dose of alemtuzumab can suppress CD4q and CD8q lymphocytes for more than one year w3x. Several randomized controlled trials using alemtuzumab in organ transplant patients other than the lung have shown similar survival and rejection but with reduced maintenance immunosuppression, and no increase in infection rate or lymphoproliferative disease w3-11x. In this study, we investigated whether alemtuzumab induction would provide rejection control using minimalist immunosuppression.
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Materials and methods

Patient population
This study was performed at the University of Maryland and patients provided informed consent for alemtuzumab. Institutional review board -approval was obtained.
From 
Immunosuppressive protocol and infection prophylaxis
Patients received 250 mg of methylprednisolone before allograft reperfusion. Alemtuzumab (30 mg) was infused over 2 h within 12 h after transplantation. Acetaminophen 650 mg, diphenhydramine 50 mg intravenously and methylprednisolone 500 mg intravenously were administered as premedications. Tacrolimus was started in both groups on postoperative day (POD) 1 (trough level ;10 ngyml). Alemtuzumab patients received 7.5 mg of prednisone once daily Downloaded from https://academic.oup.com/icvts/article-abstract/10/2/190/644574 by guest on 21 January 2019 Table 1 Characteristics of lung transplant recipients in the alemtuzumab and control groups
Controls
Alemtuzumab P-value (ns20) ( ns20)
African-American 35% (7y20) 45% (9y20) 0.519 Caucasian 65% (13y20) 55% (11y20) Average age (years) 56.1"11.7 57.9"11.9 0.641 on POD 1. Control patients received 375 mg of methylprednisolone and were started on 15-20 mg of prednisone once a day. Alemtuzumab patients received 250 mg of mycophenolate mofetil (MMF) twice a day whereas control patients received 750 mg twice a day.
Patients who were mismatches for cytomegalovirus (CMV) received valganciclovir 900 mg daily for six months. All other CMV combinations received valganciclovir 450 mg daily for six months. Fungal prophylaxis consisted of voriconazole 200 mg twice daily for six months.
Treatment of rejection
Histological examination of transbronchial biopsy was performed according to standard criteria. Significant acute rejection (AR) (grade A2 or higher) was treated with solumedrol 1 g daily for three days or with anti-thymocyte globulin (thymoglobulin, ATG) 1.5 mgykg daily for five days.
Post-transplant monitoring
Bronchoscopy with bronchoalveolar lavage (BAL) and transbronchial biopsy was performed every three months post-transplantation for one year and when clinically indicated after the first post-transplant year. Pulmonary function testing was performed at discharge and at three-month intervals for the first postoperative year in accordance with ATS standards. Bronchiolitis obliterans syndrome is defined as a sustained decrease in forced expiratory volume in 1 s (FEV ) of at least 20% from the individual patient's maxi-1 mum values w12x.
Definitions
Significant infections are defined by BAL if bacterial cultures demonstrated G10,000 colony forming units per ml and or if viral antigen or culture or fungal culture was positive. Cycles of antibiotics, antiviral agents or antifungal medications were quantitated for all subjects.
Statistical methods
Survival and freedom-from-rejection analyses were performed using the Kaplan-Meier method with log-rank analysis. Continuous variables were compared using the Student's t-test or Wilcoxon rank-sum test. Categorical values were compared using the x or Fisher's exact test. Average trough levels for tacrolimus and prednisone and MMF doses were analyzed at 30"15 days, 180"30 days and 360"30 days. P-values were reported as two-tailed. Pvalues were significant if F0.05. Values are reported as means"standard deviation (S.D.). All analyses were conducted with the use of SPSS 15.0 software.
Results
Demographics
Baseline demographics are shown in Table 1 . The average follow-up time for the alemtuzumab and control group was 287 days (range 61-528) and 798 days (range 558-1042), respectively. There were five patients in both the alemtuzumab and control group who experienced grade two or three primary graft dysfunction within 72 h after transplantation. Table 2 shows maintenance immunosuppression. Tacrolimus levels at one month post-transplant are significantly lower in alemtuzumab patients (9.3"3.2 vs. 11.2"3.6; Ps0.004) whereas all levels at other intervals were similar. MMF dosages were lower in the alemtuzumab group at all intervals and similarly prednisone was lower at one and at six months after transplantation. 
Maintenance immunosuppression
Survival
Estimated six-month survival was not significantly different between the groups (90% in the alemtuzumab group vs. 95% in the control group, Ps0.52) with a mean survival time of 0.48 years in the control group (95% confidence interval (CI), 0.45-0.52) vs. 0.47 years in the alemtuzumab group (95% CI 0.43-0.52). Survival at 12 months posttransplantation for alemtuzumab patients was 76% compared to 95% in controls (Ps0.19, Fig. 1 ). Mean survival time was 0.96 years for controls (95% CI 0.88-1.04) vs. 0.91 years in alemtuzumab (95% CI 0.80-1.02). Two control patients died, one from CMV pneumonitis and the second from chronic rejection. Three deaths in the alemtuzumab group were due to adult respiratory distress syndrome, infectious colitis and sepsis. Two patients were retransplanted, one in both the alemtuzumab and control group on POD 423 and 34, respectively. Combined patient and graft survival at six months was 90% in both groups (Ps1.00).
Acute rejection and lymphocytic bronchitis
No differences in episodes of AR were observed (GA2 within six months: 2y16 alemtuzumab vs. 5y20 controls, Ps0.43), high-grade AR (GA3: 1y16 alemtuzumab vs. 0y20 controls, Ps0.44) or lymphocytic bronchiolitis (LB) (3y16 alemtuzumab vs. 4y20 controls, Ps1.00). There was no difference in the incidence of LB or AR (LB 0.3"0.6 per patient per year in the alemtuzumab group vs. 0.2"0.4 in the control group, Ps0.69; AR 0.8"1.7 per patient per year in the alemtuzumab group and 0.5"0.8 in the control group, Ps0.55) (see Figs. 2 and 3) . Obliterative bronchiolitis was observed on biopsies in two control patients, one at POD 139 and the other at POD 311. No evidence of obliterative bronchiolitis was observed on pathology from the alemtuzumab patients.
Similarly, no differences in solumedrol and anti-thymocyte globulin courses were observed (solumedrol 1.23"1.65 per patient per year alemtuzumab vs. 0.44"0.74 controls, Ps0.24; ATG 0.10"0.30 per patient per year vs. 0.13" 0.28, Ps0.50).
Infection
There was no difference in bacteria positive BAL cultures (alemtuzumab 4.9"7.3 per patient per year vs. controls 2.7"3.3, Ps0.26), or viral or fungal isolates (alemtuzumab viral rate 0.4"1.4 per patient per year vs. controls 0.1"0.3, Ps0.87; alemtuzumab fungal rate 3.9"6.6 per patient per year vs. controls 2.3"1.9, Ps0.57, respectively). Aspergillus fumigatus was isolated within 30 days of transplantation from bronchoscopic anastomotic cultures in two control patients but no patient in the alemtuzumab cohort. Antibacterial treatments in the alemtuzumab group as compared to the controls were similar (alemtuzumab 4.6"5.4 courses per patient per year vs. controls 2.9"4.6, Ps0.22). Antiviral and antifungal treatments were similar (antiviral alemtuzumab 0.7"1.9 per patient per year vs. controls 1.5"4.2, Ps0.11; antifungal alemtuzumab 1.7" 2.2 per patient per year vs. controls 1.1"1.7, Ps0.65). post-transplantation. The initial forced vital capacity (FVC) value was significantly lower in the alemtuzumab group as compared to control patients (1.76"0.46 l vs. 2.14"0.49 l, Ps0.03). No other significant differences were identified. Airway stenting was required in one alemtuzumab and two control patients for airway strictures.
Pulmonary function
Hospital stay
Hospital stay was similar between the two groups (23"18 days for alemtuzumab vs. 22"18 for controls, Ps0.80).
Laboratory parameters
Initial creatinine within 30 days after transplantation was higher among alemtuzumab patients as compared to the controls (1.32"0.87 mgydl vs. 1.17"0.49 mgydl, P-0.001). Renal function subsequently improved in alemtuzumab patients (3-6 months 1.07"0.79 mgydl vs. 1.52"0.71 mgydl, P-0.001; 6-9 months 0.73"0.39 vs. 1.41"0.33, P-0.001; 9-12 months 0.85"0.39 vs. 2.25" 1.44, P-0.001). Initial glucose levels in the alemtuzumab group were significantly lower than in the control group (112"39 mgydl vs. 124"39 mgydl, P-0.001).
Immunosuppression parameters
Lymphocyte counts were lower in alemtuzumab patients at all intervals (Table 3 ). There were no significant differences in the number of filgrastim courses used for neutropenia administered to the two groups (alemtuzumab 0.65"1.19 per patient per year vs. control 0.18"0.44, Ps0.29).
Discussion
In this study, we compare alemtuzumab induction therapy combined with low-dose maintenance immunosuppression to standard immunosuppression without induction after lung transplantation. Although survival was similar in both groups, those patients receiving alemtuzumab required substantially less oral immunosuppression. Six-and 12-month patients survival after alemtuzumab of 90% and 76% is similar to our controls receiving standard immunosuppression without induction and is comparable to the 78% 12-month survival reported by the ISHLT registry w2x. Despite a significant study limitation in terms of duration of follow-up, AR and LB occurred with no increased frequency using minimal immunosuppression after alemtuzumab.
Nearly universal immunosuppressive drug specific toxicities and complications of infection due to immune depression underscore the need for new therapeutic regimens. Reduced creatinine and serum glucose seen after alemtuzumab induction appear to have resulted from decreased immunosuppression as evidenced by substantially lower tacrolimus levels and steroid doses. Moreover, there was no increased infection risk with alemtuzumab induction. Pitfalls of this study are numerous and include the small number of patients enrolled with limited follow-up particularly in the alemtuzumab cohort, the absence of randomization and the retrospective nature of controls. Since the median time to diagnosis of bronchiolitis obliterans syndrome is 16-20 months w13x, longer follow-up is needed to evaluate the effect of alemtuzumab. Whether minimal immune suppression is associated with differences in survival )12 months after transplantation will also need to be determined.
The CD52 antigen is a short glycosylphosphatidylinositol anchored protein attached to the outer layer of the cell Downloaded from https://academic.oup.com/icvts/article-abstract/10/2/190/644574 by guest on 21 January 2019 membrane w14x. In 1983, Hale found that the rat IgM antibody Campath-1 is a potent lymphocyte depleting drug which depletes peripheral blood lymphocytes w15x. The humanized antibody alemtuzumab is found to have identical specificity to the original rat antibody w3x. The extent and duration of lymphocyte depletion is thought to correlate with rejection prevention. Numerous studies in kidney but just one in lung transplant recipients have shown alemtuzumab induction decreases the need for systemic immunosuppression and that survival is similar to conventional immunosuppressive protocols that either did not use induction or used other induction therapies w5-11x. McCurry et al. had compared alemtuzumab induction immediately prior to lung transplantation followed by tacrolimus nearmonotherapy to both thymoglobulin or daclizumab induction therapy followed by conventional triple-drug immunosuppression. After six months of follow-up, results showed similar survival rates between their three induction groups, but less rejection in the alemtuzumab cohort w9x. Their survival of 90% is similar to our six-month survival using alemtuzumab.
The minimum quantity of immunosuppression needed to achieve comparable results to standard high-dose tripledrug immunosuppressive regimens has not been determined. Since immunosuppressive toxicities using standard triple-drug regimens are common, this seems to be a logical question that should be addressed by future controlled trials. Although we cannot answer this question, in our single-center experience in a relatively small number of patients, survival and AR after alemtuzumab with minimal maintenance immune suppression was no worse than using high-dose immunosuppression without induction and survival is comparable to ISHLT results. Nonetheless, a firm conclusion in reference to the potential benefit of alemtuzumab induction cannot be drawn based on this study due to the retrospective nature of controls and relatively small sample size. Further follow-up of our study patients and a prospective randomized trial will be needed to confirm these findings and to evaluate whether the eventual penalty for reduced dose immune suppression is chronic allograft dysfunction.
